Egetis Therapeutics invites investors to a Capital Markets Day, mark your calendars for December 19 at 15.00-18.00.

 

During the event, the Company will update and review its strategy and pipeline. The presentations will focus on the unmet medical need, development plans, pre-launch activities, and commercialization plans for the investigational drug Emcitate (tiratricol), being developed as a possible treatment for MCT8 deficiency, as well as additional activities to create and enhance long-term shareholder value.

 

About Egetis Theraputics

Egetis is an innovative and integrated pharmaceutical company, focused on projects in late clinical development phase for commercialization in the field of orphan drugs for the treatment of serious and rare diseases with significant medical needs.